Tinavi Medical vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tinavi Medical Technologies Co Ltd (688277.CG)

Q3 202615 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

July 202615 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

Latest15 Jul – 29 Jul 2026

▲2

Tinavi to buy 62% of Shanghai Orthopedics, adding implants to robot business

Tinavi to acquire 62% of Shanghai Orthopedics via share issuance Tinavi will buy a 62% controlling stake in Shanghai Minimally Invasive Orthopedics, a maker of joint implants, using newly issued shares. This fills the missing implant part of its product line, letting it sell robots plus implants together. The stock resumes trading July 30.
This is the core new event that directly changes Tinavi's business and drives the stock.
Deal creates robot-plus-implant synergy and long-term growth potential Combining Tinavi's surgical robots with Shanghai Orthopedics' hip and knee implants should boost sales through shared hospitals and doctors, and speed up new product development. The target's knee implant has a strong 17-year survival rate and sells in the US, Japan and Europe.
Explains why the acquisition could lift future earnings, not just headline news.
Deal is still subject to approvals and due diligence The acquisition is a major restructuring and needs regulatory approvals, due diligence and a formal agreement. It could still fall through. Also, paying with new shares dilutes existing shareholders, though the company says control will not change.
Provides the real counterweight: execution risk and share dilution could cap gains.

Integer Holdings Corp (ITGR)

Q3 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

July 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

Latest17 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.